{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T07:26:37Z","timestamp":1787037997669,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00228-026-04151-2","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:55:47Z","timestamp":1785542147000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular safety of psilocybin in psychiatric practice: a narrative review"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0973-5455","authenticated-orcid":false,"given":"Lukasz","family":"Szarpak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2140-9732","authenticated-orcid":false,"given":"Michal","family":"Pruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5648-4652","authenticated-orcid":false,"given":"Damian","family":"Swieczkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8333-0204","authenticated-orcid":false,"given":"Bernard","family":"Rybczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3431-4417","authenticated-orcid":false,"given":"Aleksandra","family":"Pieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6343-8454","authenticated-orcid":false,"given":"Wies\u0142aw Jerzy","family":"Cuba\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,1]]},"reference":[{"key":"4151_CR1","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","volume":"78","author":"AK Davis","year":"2021","unstructured":"Davis AK, Barrett FS, May DG et al (2021) Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry 78:481\u2013489. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.3285","journal-title":"JAMA Psychiatry"},{"key":"4151_CR2","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin GM, Aaronson ST, Alvarez O et al (2022) Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med 387:1637\u20131648. https:\/\/doi.org\/10.1056\/NEJMoa2206443","journal-title":"N Engl J Med"},{"key":"4151_CR3","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1176\/appi.ajp.2019.19010035","volume":"177","author":"CM Reiff","year":"2020","unstructured":"Reiff CM, Richman EE, Nemeroff CB et al (2020) Psychedelics and psychedelic-assisted psychotherapy. Am J Psychiatry 177:391\u2013410. https:\/\/doi.org\/10.1176\/appi.ajp.2019.19010035","journal-title":"Am J Psychiatry"},{"key":"4151_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101809","volume":"56","author":"R von Rotz","year":"2022","unstructured":"von Rotz R, Schindowski EM, Jungwirth J et al (2022) Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine 56:101809. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101809","journal-title":"EClinicalMedicine"},{"key":"4151_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103517","volume":"89","author":"MM Hosein","year":"2025","unstructured":"Hosein MM, Reid MJ, Walser S et al (2025) Considerations and cautions for the integration of psilocybin into routine clinical care: a consensus statement from the US National Network of Depression Centers\u2019 Task Group on Psychedelics and Related Compounds. eClinicalMedicine 89:103517. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103517","journal-title":"EClinicalMedicine"},{"key":"4151_CR6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s44161-025-00608-2","volume":"4","author":"A Nahlawi","year":"2025","unstructured":"Nahlawi A, Ptaszek LM, Ruskin JN (2025) Cardiovascular effects and safety of classic psychedelics. Nat Cardiovasc Res 4:131\u2013144. https:\/\/doi.org\/10.1038\/s44161-025-00608-2","journal-title":"Nat Cardiovasc Res"},{"key":"4151_CR7","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1177\/00048674241289024","volume":"59","author":"RR Freitas","year":"2025","unstructured":"Freitas RR, Gotsis ES, Gallo AT et al (2025) The safety of psilocybin-assisted psychotherapy: a systematic review. Aust N Z J Psychiatry 59:128\u2013151. https:\/\/doi.org\/10.1177\/00048674241289024","journal-title":"Aust N Z J Psychiatry"},{"key":"4151_CR8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00213-003-1640-6","volume":"172","author":"F Hasler","year":"2004","unstructured":"Hasler F, Grimberg U, Benz MA et al (2004) Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology 172:145\u2013156. https:\/\/doi.org\/10.1007\/s00213-003-1640-6","journal-title":"Psychopharmacology"},{"key":"4151_CR9","doi-asserted-by":"publisher","first-page":"938","DOI":"10.3390\/jcm11040938","volume":"11","author":"CL Yu","year":"2022","unstructured":"Yu CL, Liang CS, Yang FC et al (2022) Trajectory of antidepressant effects after single- or two-dose administration of psilocybin: a systematic review and multivariate meta-analysis. J Clin Med 11:938. https:\/\/doi.org\/10.3390\/jcm11040938","journal-title":"J Clin Med"},{"key":"4151_CR10","doi-asserted-by":"publisher","first-page":"1359088","DOI":"10.3389\/fpsyt.2024.1359088","volume":"15","author":"S Fang","year":"2024","unstructured":"Fang S, Yang X, Zhang W (2024) Efficacy and acceptability of psilocybin for primary or secondary depression: a systematic review and meta-analysis of randomized controlled trials. Front Psychiatry 15:1359088. https:\/\/doi.org\/10.3389\/fpsyt.2024.1359088","journal-title":"Front Psychiatry"},{"key":"4151_CR11","doi-asserted-by":"publisher","first-page":"104060","DOI":"10.1016\/j.nsa.2024.104060","volume":"3","author":"I Straumann","year":"2024","unstructured":"Straumann I, Holze F, Becker AM et al (2024) Safety pharmacology of acute psilocybin administration in healthy participants. Neurosci Appl 3:104060. https:\/\/doi.org\/10.1016\/j.nsa.2024.104060","journal-title":"Neurosci Appl"},{"issue":"4","key":"4151_CR12","doi-asserted-by":"publisher","first-page":"e245960","DOI":"10.1001\/jamanetworkopen.2024.5960","volume":"7","author":"A Yerubandi","year":"2024","unstructured":"Yerubandi A, Thomas JE, Bhuiya NMMA et al (2024) Acute adverse effects of therapeutic doses of psilocybin: a systematic review and meta-analysis. JAMA Netw Open 7:e245960. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.5960","journal-title":"JAMA Netw Open"},{"key":"4151_CR13","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jamapsychiatry.2024.2546","volume":"81","author":"JT Hinkle","year":"2024","unstructured":"Hinkle JT, Graziosi M, Nayak SM et al (2024) Adverse events in studies of classic psychedelics: a systematic review and meta-analysis. JAMA Psychiatry 81:1225\u20131235. https:\/\/doi.org\/10.1001\/jamapsychiatry.2024.2546","journal-title":"JAMA Psychiatry"},{"key":"4151_CR14","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1001\/jamapsychiatry.2026.0132","volume":"83","author":"LJ Mertens","year":"2026","unstructured":"Mertens LJ, Koslowski M, Betzler F et al (2026) Efficacy and safety of psilocybin in treatment-resistant major depression: the EPISODE randomized clinical trial. JAMA Psychiatry 83:448\u2013460. https:\/\/doi.org\/10.1001\/jamapsychiatry.2026.0132","journal-title":"JAMA Psychiatry"},{"key":"4151_CR15","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1007\/s43440-023-00539-4","volume":"75","author":"A Ws\u00f3\u0142","year":"2023","unstructured":"Ws\u00f3\u0142 A (2023) Cardiovascular safety of psychedelic medicine: current status and future directions. Pharmacol Rep 75:1362\u20131380. https:\/\/doi.org\/10.1007\/s43440-023-00539-4","journal-title":"Pharmacol Rep"},{"key":"4151_CR16","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1177\/10600280231205645","volume":"58","author":"D Kaminski","year":"2024","unstructured":"Kaminski D, Reinert JP (2024) The tolerability and safety of psilocybin in psychiatric and substance-dependence conditions: a systematic review. Ann Pharmacother 58:811\u2013826. https:\/\/doi.org\/10.1177\/10600280231205645","journal-title":"Ann Pharmacother"},{"key":"4151_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2025.111541","volume":"143","author":"D Bukovsky","year":"2025","unstructured":"Bukovsky D, Amaev A, Song J et al (2025) Adverse event reporting and management in psilocybin therapy clinical trials: a systematic review to guide clinical and research protocol development. Prog Neuropsychopharmacol Biol Psychiatry 143:111541. https:\/\/doi.org\/10.1016\/j.pnpbp.2025.111541","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"4151_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/02698811231215420","volume":"38","author":"L Bouchet","year":"2024","unstructured":"Bouchet L, Sager Z, Yrondi A et al (2024) Older adults in psychedelic-assisted therapy trials: a systematic review. J Psychopharmacol 38:33\u201348. https:\/\/doi.org\/10.1177\/02698811231215420","journal-title":"J Psychopharmacol"},{"key":"4151_CR19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jagp.2022.08.007","volume":"31","author":"CB Johnston","year":"2023","unstructured":"Johnston CB, Mangini M, Grob C et al (2023) The safety and efficacy of psychedelic-assisted therapies for older adults: knowns and unknowns. Am J Geriatr Psychiatry 31:44\u201353. https:\/\/doi.org\/10.1016\/j.jagp.2022.08.007","journal-title":"Am J Geriatr Psychiatry"},{"key":"4151_CR20","doi-asserted-by":"publisher","first-page":"104706","DOI":"10.1016\/j.neubiorev.2022.104706","volume":"139","author":"V Polito","year":"2022","unstructured":"Polito V, Liknaitzky P (2022) The emerging science of microdosing: a systematic review of research on low-dose psychedelics (1955\u20132021) and recommendations for the field. Neurosci Biobehav Rev 139:104706. https:\/\/doi.org\/10.1016\/j.neubiorev.2022.104706","journal-title":"Neurosci Biobehav Rev"},{"key":"4151_CR21","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1001\/jamapsychiatry.2025.3038","volume":"83","author":"KE Hutchison","year":"2026","unstructured":"Hutchison KE, Hooper JF, Karoly HC (2026) Psilocybin outside the clinic: public health challenges of increasing publicity, accessibility, and use. JAMA Psychiatry 83:78\u201384. https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.3038","journal-title":"JAMA Psychiatry"},{"key":"4151_CR22","doi-asserted-by":"publisher","first-page":"486","DOI":"10.3390\/jof12070486","volume":"12","author":"A Sharchaton","year":"2026","unstructured":"Sharchaton A, Parsha S, Azerrad SP et al (2026) Surprising variability in tryptamine profiles of Psilocybe cubensis fruiting bodies: inter- and intra-strain differences across 14 strains cultivated under controlled conditions. J Fungi (Basel) 12:486. https:\/\/doi.org\/10.3390\/jof12070486","journal-title":"J Fungi (Basel)"},{"key":"4151_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.aca.2023.342161","volume":"1288","author":"R Goff","year":"2024","unstructured":"Goff R, Smith M, Islam S et al (2024) Determination of psilocybin and psilocin content in multiple Psilocybe cubensis mushroom strains using liquid chromatography-tandem mass spectrometry. Anal Chim Acta 1288:342161. https:\/\/doi.org\/10.1016\/j.aca.2023.342161","journal-title":"Anal Chim Acta"},{"key":"4151_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/02698811231211219","volume":"38","author":"A Halman","year":"2024","unstructured":"Halman A, Kong G, Sarris J et al (2024) Drug-drug interactions involving classic psychedelics: a systematic review. J Psychopharmacol 38:3\u201318. https:\/\/doi.org\/10.1177\/02698811231211219","journal-title":"J Psychopharmacol"},{"key":"4151_CR25","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s00213-022-06083-y","volume":"239","author":"A Sarparast","year":"2022","unstructured":"Sarparast A, Thomas K, Malcolm B et al (2022) Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology (Berl) 239:1945\u20131976. https:\/\/doi.org\/10.1007\/s00213-022-06083-y","journal-title":"Psychopharmacology (Berl)"},{"key":"4151_CR26","doi-asserted-by":"publisher","first-page":"1391689","DOI":"10.3389\/fphar.2024.1391689","volume":"15","author":"J Thomann","year":"2024","unstructured":"Thomann J, Kolaczynska KE, Stoeckmann OV et al (2024) In vitro and in vivo metabolism of psilocybin\u2019s active metabolite psilocin. Front Pharmacol 15:1391689. https:\/\/doi.org\/10.3389\/fphar.2024.1391689","journal-title":"Front Pharmacol"},{"key":"4151_CR27","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/cpt.2487","volume":"111","author":"AM Becker","year":"2022","unstructured":"Becker AM, Holze F, Grandinetti T et al (2022) Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects. Clin Pharmacol Ther 111:886\u2013895. https:\/\/doi.org\/10.1002\/cpt.2487","journal-title":"Clin Pharmacol Ther"},{"key":"4151_CR28","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1177\/02698811231179910","volume":"37","author":"N Gukasyan","year":"2023","unstructured":"Gukasyan N, Griffiths RR, Yaden DB et al (2023) Attenuation of psilocybin mushroom effects during and after SSRI\/SNRI antidepressant use. J Psychopharmacol 37:707\u2013716. https:\/\/doi.org\/10.1177\/02698811231179910","journal-title":"J Psychopharmacol"},{"key":"4151_CR29","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/cpdd.796","volume":"10","author":"E Dahmane","year":"2021","unstructured":"Dahmane E, Hutson PR, Gobburu JVS (2021) Exposure-response analysis to assess the concentration-QTc relationship of psilocybin\/psilocin. Clin Pharmacol Drug Dev 10:78\u201385. https:\/\/doi.org\/10.1002\/cpdd.796","journal-title":"Clin Pharmacol Drug Dev"},{"key":"4151_CR30","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/ijnp\/pyab085","volume":"25","author":"B Hackl","year":"2022","unstructured":"Hackl B, Todt H, Kubista H et al (2022) Psilocybin therapy of psychiatric disorders is not hampered by hERG potassium channel-mediated cardiotoxicity. Int J Neuropsychopharmacol 25:280\u2013282. https:\/\/doi.org\/10.1093\/ijnp\/pyab085","journal-title":"Int J Neuropsychopharmacol"},{"key":"4151_CR31","unstructured":"International Council for Harmonisation (2005) ICH E14: The clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Accessed 10 July 2026. https:\/\/database.ich.org\/sites\/default\/files\/E14_Guideline.pdf"},{"key":"4151_CR32","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10928-025-09985-4","volume":"52","author":"Y Ji","year":"2025","unstructured":"Ji Y, Johannesen L, Garnett C (2025) FDA\u2019s insights: implementing new strategies for evaluating drug-induced QTc prolongation. J Pharmacokinet Pharmacodyn 52:37. https:\/\/doi.org\/10.1007\/s10928-025-09985-4","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"4151_CR33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.toxlet.2024.06.006","volume":"398","author":"J Neumann","year":"2024","unstructured":"Neumann J, Dimov K, Azatsian K et al (2024) Effects of psilocin and psilocybin on human 5-HT4 serotonin receptors in atrial preparations of transgenic mice and humans. Toxicol Lett 398:55\u201364. https:\/\/doi.org\/10.1016\/j.toxlet.2024.06.006","journal-title":"Toxicol Lett"},{"key":"4151_CR34","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1038\/sj.bjp.0705553","volume":"140","author":"D Pau","year":"2003","unstructured":"Pau D, Workman AJ, Kane KA et al (2003) Electrophysiological effects of 5-hydroxytryptamine on isolated human atrial myocytes, and the influence of chronic beta-adrenoceptor blockade. Br J Pharmacol 140:1434\u20131441. https:\/\/doi.org\/10.1038\/sj.bjp.0705553","journal-title":"Br J Pharmacol"},{"key":"4151_CR35","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S0008-6363(98)00198-9","volume":"40","author":"R Pino","year":"1998","unstructured":"Pino R, Cerbai E, Calamai G et al (1998) Effect of 5-HT4 receptor stimulation on the pacemaker current I(f) in human isolated atrial myocytes. Cardiovasc Res 40:516\u2013522. https:\/\/doi.org\/10.1016\/S0008-6363(98)00198-9","journal-title":"Cardiovasc Res"},{"key":"4151_CR36","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/JCP.0000000000002197","volume":"46","author":"E Kervadec","year":"2026","unstructured":"Kervadec E, Bezo A, Serreau R et al (2026) Thirty years of ibogaine research: a literature review on clinical perspectives. J Clin Psychopharmacol 46:440\u2013450. https:\/\/doi.org\/10.1097\/JCP.0000000000002197","journal-title":"J Clin Psychopharmacol"},{"key":"4151_CR37","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1016\/S0002-9440(10)64489-6","volume":"161","author":"B Jian","year":"2002","unstructured":"Jian B, Xu J, Connolly J et al (2002) Serotonin mechanisms in heart valve disease I: serotonin-induced up-regulation of transforming growth factor-beta1 via G-protein signal transduction in aortic valve interstitial cells. Am J Pathol 161:2111\u20132121. https:\/\/doi.org\/10.1016\/S0002-9440(10)64489-6","journal-title":"Am J Pathol"},{"key":"4151_CR38","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","volume":"102","author":"RB Rothman","year":"2000","unstructured":"Rothman RB, Baumann MH, Savage JE et al (2000) Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102:2836\u20132841. https:\/\/doi.org\/10.1161\/01.CIR.102.23.2836","journal-title":"Circulation"},{"key":"4151_CR39","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1002\/pds.2044","volume":"19","author":"A Weill","year":"2010","unstructured":"Weill A, Paita M, Tuppin P et al (2010) Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus. Pharmacoepidemiol Drug Saf 19:1256\u20131262. https:\/\/doi.org\/10.1002\/pds.2044","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"4151_CR40","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1056\/NEJMoa062222","volume":"356","author":"R Schade","year":"2007","unstructured":"Schade R, Andersohn F, Suissa S et al (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356:29\u201338. https:\/\/doi.org\/10.1056\/NEJMoa062222","journal-title":"N Engl J Med"},{"key":"4151_CR41","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1021\/acsptsci.2c00177","volume":"5","author":"GC Glatfelter","year":"2022","unstructured":"Glatfelter GC, Pottie E, Partilla JS et al (2022) Structure-activity relationships for psilocybin, baeocystin, aeruginascin, and related analogues to produce pharmacological effects in mice. ACS Pharmacol Transl Sci 5:1181\u20131196. https:\/\/doi.org\/10.1021\/acsptsci.2c00177","journal-title":"ACS Pharmacol Transl Sci"},{"key":"4151_CR42","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.euroneuro.2016.05.001","volume":"26","author":"A Rickli","year":"2016","unstructured":"Rickli A, Moning OD, Hoener MC et al (2016) Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol 26:1327\u20131337. https:\/\/doi.org\/10.1016\/j.euroneuro.2016.05.001","journal-title":"Eur Neuropsychopharmacol"},{"key":"4151_CR43","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1177\/02698811231190865","volume":"37","author":"M Tagen","year":"2023","unstructured":"Tagen M, Mantuani D, van Heerden L et al (2023) The risk of chronic psychedelic and MDMA microdosing for valvular heart disease. J Psychopharmacol 37:876\u2013890. https:\/\/doi.org\/10.1177\/02698811231190865","journal-title":"J Psychopharmacol"},{"key":"4151_CR44","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1177\/02698811231225609","volume":"38","author":"A Rouaud","year":"2024","unstructured":"Rouaud A, Calder AE, Hasler G (2024) Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: comparison to known cardiotoxins. J Psychopharmacol 38:217\u2013224. https:\/\/doi.org\/10.1177\/02698811231225609","journal-title":"J Psychopharmacol"},{"key":"4151_CR45","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1080\/14740338.2023.2248883","volume":"22","author":"RS McIntyre","year":"2023","unstructured":"McIntyre RS (2023) Serotonin 5-HT2B receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents. Expert Opin Drug Saf 22:881\u2013883. https:\/\/doi.org\/10.1080\/14740338.2023.2248883","journal-title":"Expert Opin Drug Saf"},{"key":"4151_CR46","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1001\/jamapsychiatry.2024.0184","volume":"81","author":"M Marks","year":"2024","unstructured":"Marks M, Brendel RW, Shachar C et al (2024) Essentials of informed consent to psychedelic medicine. JAMA Psychiatry 81:611\u2013617. https:\/\/doi.org\/10.1001\/jamapsychiatry.2024.0184","journal-title":"JAMA Psychiatry"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04151-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04151-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04151-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:55:29Z","timestamp":1787036129000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04151-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4151"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04151-2","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"16 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This manuscript is a narrative review of previously published literature and did not involve new studies in humans or animals performed by the authors.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During preparation of this submission, the authors used OpenAI ChatGPT to assist with language editing and adaptation to journal formatting requirements. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the submitted manuscript.","order":2,"name":"Ethics","label":"Declaration of generative AI and AI-assisted technologies in the manuscript preparation process","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Lukasz Szarpak, Michal Pruc, Damian Swieczkowski, Bernard Rybczynski, and Aleksandra Pieta declare no conflicts of interest. Wies\u0142aw Jerzy Cuba\u0142a reports grants from Acadia, Alkermes, Allergan, Angelini, Auspex Pharmaceuticals, Beckley Psytech, BMS, Celon, Cephalon, Compass Pathways, Cortexyme, Ferrier, Forest Laboratories, Gedeon Richter, GH Research, GW Pharmaceuticals, HMNC Brain Health, IntraCellular Therapies, Janssen, KCR, Lilly, Lundbeck, Minerva, MSD, NIH, Neumora, Novartis, Orion, Otsuka, Recognify Life Sciences, Sanofi, and Servier; honoraria from Adamed, Angelini, AstraZeneca, BMS, Celon, GH Research, GSK, Janssen, KRKA, Lekam, Lundbeck, Minerva, NeuroCog, Novartis, Orion, Pfizer, Polfa Tarchomin, Sanofi, Servier, and Zentiva; and advisory board participation for Angelini, Celon (ended 2021), Douglas Pharmaceuticals, GH Research, Janssen, MSD, Novartis, Polpharma, Sanofi, and Tasman Therapeutics.","order":5,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"223"}}